Company / SG&A Expense
Haemonetics SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$436.8M
FY2024
5-year range
$340.1M / $436.8M
FY2020-FY2024
Trend
+1.2%
vs FY2023
Sector context
#72 of 152
Health Care
What the data says
At $437M, Haemonetics's sg&a expense ranks #81 of 152 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $275M in FY2020 to $437M in FY2024.
Based on SEC 10-K filings.
$437M in FY2024 with a 5-year CAGR of +9.1%.
Increased from $377M to $437M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +8.7%
- 5-Year CAGR
- +9.1%
- 10-Year CAGR
- -
Sector benchmark
#81 of 152 in Health CareTop 53% of 152This company $436.8M Sector average $182.7B
▼
-99.8% below sector average
Key checks
Key Insights
- Haemonetics's sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +9.1%, indicating consistent growth.
- In FY2024, sg&a expense increased 1.2% year-over-year.
- Ranks #72 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $436.8M | +1.2% |
| FY2023 | $431.8M | +14.6% |
| FY2022 | $376.7M | +10.7% |
| FY2021 | $340.1M | +23.6% |
| FY2020 | $275.2M | -2.4% |
| FY2019 | $282.0M | +3.1% |
| FY2018 | $273.5M | -13.6% |
| FY2017 | $316.5M | +4.9% |
| FY2016 | $301.7M | -4.9% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026